It is encouraging to see a new treatment option for fibromyalgia after more than 15 years without a new FDA-approved therapy. But we should look beyond whether a trial met its statistical endpoint and ask a more practical question: how much better did patients actually feel?
Recent News
When axSpA does not respond to treatment and both the clinician and patient perceive this is a problem, we call it difficult to manage. Is the disease difficult, or are we failing to see it clearly?Read Article
ILD is a particularly worrisome systemic feature of SjD that may be associated with poorer quality of life outcomes and increased mortality. Prevalence of SjD-ILD has been quoted to occur in 10-20% of SjD patients; however, identification of SjD may vary widely based on the testing methodologies used.
Relapse after CD19 CAR-T was rare in lupus and common in anti-synthetase syndrome and Scl-70 scleroderma. Six of seven relapsing patients were treated with BCMA-directed therapy and responded again.
Today the US Food and Drug Administration (FDA) approved secukinumab (Cosentyx) for the treatment of adults with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. This is the first anti-IL-17 biologic approved for people living with PMR.

Poster Hall